Fifth Third Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Fifth Third Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Buy	+5,075	New	+$208K	0.01%	746

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Fifth Third Wealth Advisors's TGTX Position: Q2 2026 in Review

Fifth Third Wealth Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 5,075 shares worth $279K. The stake represents 0.01% of the portfolio and ranks #746 among its holdings.

429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Fifth Third Wealth Advisors held 5,075 shares of TG Therapeutics worth $279K as of Q2 2026.
TG Therapeutics was a new Fifth Third Wealth Advisors position in Q2 2026.
TG Therapeutics made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #746 holding.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.